Is the conquest of Hepatitis C imminent?

Abstract Hepatitis C virus represents a global pathogen of human health significance. In the space of less than three decades, we have witnessed the discovery of the virus, a growing understanding of the structure and biology of the viral-encoded proteins and their interaction with the host cell and the sequencing of the viral genome. Most importantly, we have moved from early therapeutic strategies aimed at crude boosting of host anti-viral immunity, limited by side effects and with poor response rates, to therapies that directly exploit our understanding of viral biology. In this review, we discuss the significance of the virus, its’ discovery and outline the advances in the molecular characterisation of the virus, before setting these within the context of contemporary and emerging therapeutic strategies as well as viral resistance mechanisms.

• Publication year

  2019

• Venue

  Expert Reviews in Molecular Medicine

• Publication date

  2019-03-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1017/erm.2019.3PMID 30909984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C Virus E2 Envelope Glycoprotein Induces an Immunoregulatory Phenotype in Macrophages

  2019cited by this paper
• New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.

  2018cited by this paper
• The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes

  2018cited by this paper
• A role for domain I of the hepatitis C virus NS5A protein in virus assembly

  2018cited by this paper
• Implementation of hepatitis C cure in Australia: one year on

  2018cited by this paper
• Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.

  2018cited by this paper
• Assessing hepatitis C spontaneous clearance and understanding associated factors—A systematic review and meta‐analysis

  2018cited by this paper
• Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors

  2018cited by this paper
• The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment

  2017cited by this paper
• Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.

  2017cited by this paper
• Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review

  2017cited by this paper
• NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

  2017cited by this paper
• Innate and Adaptive Immune Responses in Chronic HCV Infection.

  2017cited by this paper
• Primer on Hepatitis C Virus Resistance to Direct-Acting Antiviral Treatment: A Practical Approach for the Treating Physician.

  2017cited by this paper
• Functional RNA structures throughout the Hepatitis C Virus genome.

  2017cited by this paper
• Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

  2017cited by this paper
• The Hepatitis C Virus NS 2 / 3 Protease

  2016cited by this paper
• Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.

  2016cited by this paper
• Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication

  2016cited by this paper
• Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

  2016cited by this paper
• The Coding Region of the HCV Genome Contains a Network of Regulatory RNA Structures.

  2016cited by this paper
• Hepatitis C virus relies on lipoproteins for its life cycle.

  2016cited by this paper
• cis-Acting RNA elements in the hepatitis C virus RNA genome.

  2015cited by this paper
• Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

  2015cited by this paper
• Hepatitis C virus drug resistance–associated substitutions: State of the art summary

  2015cited by this paper
• From non-A, non-B hepatitis to hepatitis C virus cure.

  2015cited by this paper
• Cryo-EM structure of Hepatitis C virus IRES bound to the human ribosome at 3.9-Å resolution

  2015cited by this paper
• Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design

  2015cited by this paper
• Structural basis for RNA replication by the hepatitis C virus polymerase

  2015cited by this paper
• Hepatitis C virus RNA functionally sequesters miR-122.

  2015cited by this paper
• Functionally conserved architecture of hepatitis C virus RNA genomes

  2015cited by this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Specific Sequence of a Beta Turn in Human La Protein May Contribute to Species Specificity of Hepatitis C Virus

  2014cited by this paper
• Natural history of hepatitis C.

  2014cited by this paper
• Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Immune responses to HCV and other hepatitis viruses.

  2014cited by this paper
• Hepatitis C virus and human miR-122: insights from the bench to the clinic.

  2014cited by this paper
• Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

  2014cited by this paper
• Update on hepatitis C virus resistance to direct-acting antiviral agents.

  2014cited by this paper
• Impact of IL28B polymorphisms on 24‐week telaprevir‐based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b

  2014cited by this paper
• Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.

  2014cited by this paper
• Next-Generation Sequencing Sheds Light on the Natural History of Hepatitis C Infection in Patients Who Fail Treatment

  2014cited by this paper
• The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection

  2014cited by this paper
• Base pairing between hepatitis C virus RNA and 18S rRNA is required for IRES-dependent translation initiation in vivo

  2014cited by this paper
• GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection

  2014cited by this paper
• IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family

  2014cited by this paper
• Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource

  2013cited by this paper
• Hepatitis C virus RNA translation.

  2013cited by this paper
• The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

  2013cited by this paper
• Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C

  2013cited by this paper
• Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure

  2013cited by this paper
• A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

  2013cited by this paper
• New therapeutic strategies in HCV: polymerase inhibitors

  2013cited by this paper
• Hepatitis-C-virus-like internal ribosome entry sites displace eIF3 to gain access to the 40S subunit

  2013cited by this paper
• Structure of the full-length HCV IRES in solution

  2013cited by this paper
• Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

  2012cited by this paper
• New Details of HCV NS3/4A Proteinase Functionality Revealed by a High-Throughput Cleavage Assay

  2012cited by this paper
• Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA

  2012cited by this paper
• Structure of a hepatitis C virus RNA domain in complex with a translation inhibitor reveals a binding mode reminiscent of riboswitches

  2012cited by this paper
• Genetics of IL28B and HCV—response to infection and treatment

  2012cited by this paper
• Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

  2012cited by this paper
• Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

  2011cited by this paper
• Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

  2011cited by this paper
• Biochemical and Morphological Properties of Hepatitis C Virus Particles and Determination of Their Lipidome*

  2010cited by this paper
• A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

  2010cited by this paper
• Resistance to direct antiviral agents in patients with hepatitis C virus infection.

  2010cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

  2009cited by this paper
• NS5A--from obscurity to new target for HCV therapy.

  2008cited by this paper
• Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

  2008cited by this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cited by this paper
• Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences.

  2007cited by this paper
• Expression studies of the core+1 protein of the hepatitis C virus 1a in mammalian cells

  2007cited by this paper
• Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

  2007cited by this paper
• Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease.

  2007cited by this paper
• The hepatitis C virus NS2/3 protease.

  2007cited by this paper
• The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy

  2007cited by this paper
• HCV and CSFV IRES domain II mediate eIF2 release during 80S ribosome assembly

  2007cited by this paper
• 3′ RNA Elements in Hepatitis C Virus Replication: Kissing Partners and Long Poly(U)

  2007cited by this paper
• Replication of hepatitis C virus

  2007cited by this paper
• Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

  2005cited by this paper
• Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study.

  2005cited by this paper
• Hepatitis C virus particles and lipoprotein metabolism.

  2005cited by this paper
• A Peptide Derived from RNA Recognition Motif 2 of Human La Protein Binds to Hepatitis C Virus Internal Ribosome Entry Site, Prevents Ribosomal Assembly, and Inhibits Internal Initiation of Translation

  2005cited by this paper
• Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

  2005cited by this paper
• Quantitative Analysis of the Hepatitis C Virus Replication Complex

  2005cited by this paper
• Complete Replication of Hepatitis C Virus in Cell Culture

  2005cited by this paper
• HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.

  2005cited by this paper
• Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

  2005cited by this paper
• The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein*

  2004cited by this paper
• Interactions between Viral Nonstructural Proteins and Host Protein hVAP-33 Mediate the Formation of Hepatitis C Virus RNA Replication Complex on Lipid Raft

  2004cited by this paper
• Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex.

  2003cited by this paper
• Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population‐based cohort study

  2003cited by this paper
• The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

  2003cited by this paper
• The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

  2002cited by this paper
• HCV RNA-dependent RNA polymerase replicates in vitro the 3' terminal region of the minus-strand viral RNA more efficiently than the 3' terminal region of the plus RNA.

  2001cited by this paper
• Hepatitis C Virus IRES RNA-Induced Changes in the Conformation of the 40S Ribosomal Subunit

  2001cited by this paper
• Replication of hepatitis C virus.

  2000cited by this paper
• Replication of the hepatitis C virus.

  2000cited by this paper
• Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study

  2000cited by this paper

• Mobile Applications (Apps) to Support the Hepatitis C Treatment: A Systematic Search in App Stores

  2020cites this paper
• Exploring Diachronic Changes of Biomedical Knowledge using Distributed Concept Representations

  2019cites this paper